Long-term Data With Ozanimod in Relapsing-Remitting Multiple Sclerosis
August 7th 2023Bruce Cree, MD, PhD, MAS, reviews the results of the long-term efficacy and safety study of ozanimod, DAYBREAK, in relapsing-remitting multiple sclerosis (RRMS) published last year. Dr Cree also discusses two other safety studies presented at the 2023 European Academy of Neurology (EAN) congress.
Selecting S1P Receptor Modulators in Multiple Sclerosis
August 7th 2023Bruce Cree, MD, PhD, MAS, discusses key considerations when selecting one of the four FDA approved sphinogine-1-phospate (S1P) receptor modulators for multiple sclerosis (MS). Dr Cree also highlights a particular adverse event observed in the extension studies of these four S1P receptor modulators.
S1P Receptor Modulators in Multiple Sclerosis
August 7th 2023Bruce Cree, MD, PhD, MAS, discusses the pathophysiology of multiple sclerosis (MS) and how sphinogine-1-phospate (S1P) receptor modulators address the underlying causes. Dr Cree also discusses the differences between the four FDA approved drugs for MS: fingolimod, siponimod, ozanimod, and ponesimod.
Subgroup Findings of the NURTURE Study, Importance of CMAP Amplitude in SMA: Thomas Crawford, MD
August 6th 2023The pediatric neurologist at Johns Hopkins Medicine provided commentary on the subgroup findings from the phase 4 NURTURE study of nusinersen (Spinraza; Biogen) in presymptomatic spinal muscular atrophy. [WATCH TIME: 3 minutes]
The Promise of Gene Therapies for the Management of Parkinson Disease: Mazen Elkurd, DO
August 3rd 2023The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed the current state of treatment for Parkinson disease and gene therapy as a promising treatment for the management of the disease. [WATCH TIME: 5 minutes]
Incorporating Digital Cognitive Assessments in Real-World Practice: Nicole Fowler, PhD
August 2nd 2023The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]
Uncovering Ethnic, Racial Differences in Multiple Sclerosis Onset: Farren B. S. Briggs, PhD, ScM
August 2nd 2023The associate professor in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine talked about the presentation of multiple sclerosis in Latinx individuals compared with White Americans. [WATCH TIME: 5 minutes]
Enhancing Consistency in Neuroimaging With AI and Image Harmonization: Lianrui Zuo, MSE
August 1st 2023The PhD student in the department of electrical and computer engineering at Johns Hopkins University discussed the use of artificial intelligence and image harmonization techniques to address the challenges caused by multisite effects in neuroimaging. [WATCH TIME: 4 minutes]
Ensuring Safe Pregnancy and Postpartum Care for Patients With Multiple Sclerosis: Anna Shah, MD
August 1st 2023The assistant professor of neurology at the University of Colorado School of Medicine talked about the importance of addressing family planning with patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Retrospectively Exploring De-Escalation of Multiple Sclerosis Medication: Carolyn H. Goldschmidt, DO
July 31st 2023The neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]
Comparing Ublituximab and Teriflunomide in Improving Fatigue in MS: Enrique Alvarez, MD, PhD
July 31st 2023The associate professor of neurology at the University of Colorado School of Medicine discussed results of phase 3 studies assessing therapeutics on the impact of fatigue experienced by patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Early Intervention and Disease Prevention With a Novel Epigenome Approach: Boris Kantor, PhD
July 28th 2023The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]
Targeting Neuroinflammation as a Novel Approach in Brain Health for Alzheimer Disease: RJ Tesi, MD
July 27th 2023The chief executive officer at INmune Bio discussed a unique approach from a phase 1 study targeting neuroinflammation in the brain to improve cognitive abilities and maintain memory. [WATCH TIME: 5 minutes]
The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhD
July 26th 2023The chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]
Concluding Thoughts on Biosimilars in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.
Biosimilar Discussion With Patients and Biosimilar Resources
Advanced practice providers share how to discuss biosimilars with patients and what resources might be useful for education on biosimilars.
Implementing Biosimilars in Clinical Practice
Amy Perrin Ross, APN, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share strategies for implementing biosimilars in clinical practice.
Clinical Pearls for Treating Relapsing-Remitting Multiple Sclerosis With S1P Receptor Modulators
July 24th 2023Krzysztof Selmaj, MD, PhD, wraps up this series highlighting strategies for educating patients with relapsing-remitting multiple sclerosis (RRMS) about sphinogine-1-phospate (S1P) receptor modulators.
Insights on Gut Bacteria and Cognitive Health from Middle-Aged Adults: Jazmyn Muhammad, BS
July 24th 2023The clinical research associate at the University of Texas Health Science Center at San Antonio discussed a study that explores the relationship between cognitive function and gut microbiome structure in middle-aged adults from the Framingham Heart Study cohort. [WATCH TIME: 4 minutes]